Hormonal Mechanisms of Sleep Restriction
NCT02256865
Completed
The purpose of this study is to study the effects of sleep restriction on the production of two hormones, cortisol and testosterone. The investigators aim to show that changing these hormones leads to insulin resistance, which is an important cause of type 2 diabetes mellitus. The investigators may also study the effect of sleep restriction on your food intake and cravings, mood, inflammation, metabolism (including bone), and other hormones. Inflammation is your body's response to stress and inj... Read More
Gender:
MALE
Ages:
Between 22 years and 45 years
Trial Updated:
11/02/2023
Locations: Los Angeles Biomedical Research Institute, Torrance, California
Conditions: Insulin Resistance
Register for Updates
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
NCT00587431
Completed
We postulate that multiple apoptototic events are indusce through testosterone depletion and repletion with taxotere given in conjunction with androgen withdrawal.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/20/2023
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Prostate Cancer
Register for Updates
Comparison of the Concentration of Estrogen and Testosterone Ratio in Male Patients With Cirrhosis and Hypotension
NCT05051293
Withdrawn
Cirrhosis is an end stage in liver disease leading to replacement of normal liver tissue with regenerative nodules surrounded by fibrous bands in response to chronic liver injury. It is the eighth leading cause of death in the United States and the thirteenth leading cause of death globally. Patients with cirrhosis have decreased spontaneous vascular resistance leading to hypotension. The mechanism of hypotension in cirrhosis is thought to be a complex result of the presence of increased level o... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Methodist Health System Clinical Research Institute, Dallas, Texas
Conditions: Hypotension, Cirrhosis
Register for Updates
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
NCT03649841
Terminated
This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer. Hormone therapy such as antiandrogen therapy may fight prostate cancer by blocking the production and interfering with the action of hormones. Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as prednisone, work in diffe... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/15/2023
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study.
NCT00398034
Withdrawn
The purpose of this pilot study is to test the effects of testosterone replacement on pain, fatigue, mood, cognition and libido in hypogonadal men on long-term opioid therapy for chronic pain.
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
10/11/2023
Locations: James J. Peters VAMC, Bronx, New York
Conditions: Pain, Hypogonadism
Register for Updates
Testosterone and Alendronate in Hypogonadal Men
NCT01460654
Terminated
This study will investigate the hypothesis that the combination of testosterone replacement and alendronate will improve bone density and parameters of bone quality more than either medication alone in older men with low testosterone levels and low bone density.
Gender:
MALE
Ages:
Between 60 years and 85 years
Trial Updated:
10/10/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hypogonadism, Osteopenia, Osteoporosis
Register for Updates
Testosterone Plus Finasteride Treatment After Spinal Cord Injury
NCT02248701
Terminated
The purpose of this study is to determine whether testosterone plus finasteride treatment will improve musculoskeletal health, neuromuscular function, body composition, and metabolic health in hypogonadal men who have experienced ambulatory dysfunction subsequent to incomplete spinal cord injury. The investigators hypothesize that this treatment will improve bone mineral density, enhance muscle size and muscle function, and improve body composition, without causing prostate enlargement.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida +1 locations
Conditions: Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injuries, Central Nervous System Diseases, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Register for Updates
Testopel ® vs. Generic Testosterone Pellets.
NCT04523480
Completed
The purpose of this study is to evaluate changes in vascular parameters in subjects receiving Testopel 75mg (one time) versus subjects receiving Compounded Testosterone pellets 100mg (one time) versus subjects receiving Compounded Testosterone pellets 200mg (one time) to participant with clinical hypogonadism.
Gender:
MALE
Ages:
Between 18 years and 75 years
Trial Updated:
07/20/2023
Locations: University of Miami, Department of Urology, Miami, Florida
Conditions: Hypogonadism
Register for Updates
Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
NCT03198728
Completed
This will be a randomized, multicenter, open-label, active-controlled, efficacy, and safety study in adult hypogonadal men. The study duration is 12 months (365 days), including a 90-day, open-label efficacy period and a 9-month (275-day) safety evaluation period.
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
06/06/2023
Locations: Central Research Associates, Inc., Birmingham, Alabama +35 locations
Conditions: Hypogonadism, Male
Register for Updates
A Clinical Study to Evaluate the Efficacy of Four Supplements on Improving Readiness for Intimacy
NCT05862519
Active Not Recruiting
This study is to evaluate the efficacy of four supplements designed to help participants get ready for sexual intimacy through improving digestion, weight management, sexual drive and stamina, and physical endurance during workouts and overall mood and quality of life. This study will be conducted as a single group, virtual trial, in which all participants will take all four supplements and complete online questionnaires. Participants will take the indicated supplements for the indicated amounts... Read More
Gender:
MALE
Ages:
Between 18 years and 44 years
Trial Updated:
05/15/2023
Locations: Citruslabs, Santa Monica, California
Conditions: Libido, Intimacy, Gastrointestinal Issues
Register for Updates
Study of Testosterone and rHGH in FSHD
NCT03123913
Completed
The purpose of this study is to investigate the safety and tolerability of combination therapy with recombinant human growth hormone (rHGH) and testosterone in adult male patients with facioscapulohumeral muscular dystrophy (FSHD) over 24 weeks.
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
05/12/2023
Locations: University of Rochester, Rochester, New York
Conditions: Facioscapulohumeral Muscular Dystrophy
Register for Updates
Does Testosterone Therapy Improve Patient-Reported Outcomes in Age-Related Testosterone Deficient Patients Undergoing Total Hip Replacement: A Randomized-Controlled Trial
NCT05722301
Withdrawn
This randomized-controlled trial will study on the effect of testosterone therapy on patients undergoing total hip replacement. Subjects will be male patients \> 50 years with testosterone deficiency undergoing total hip replacement due to severe degenerative joint disease. All participants will receive a total hip replacement and will be randomized to either testosterone therapy or placebo. A total of 80 subjects will be recruited randomized into 2 groups of 40 subjects. Testosterone therapy wi... Read More
Gender:
MALE
Ages:
50 years and above
Trial Updated:
02/01/2023
Locations: American Hip Institute Research Foundation, Des Plaines, Illinois
Conditions: Arthroplasty, Replacement, Hip
Register for Updates